Key result
Tocilizumab resolves symptoms in steroid-refractory juvenile Takayasu arteritis.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
Tocilizumab may be an effective alternative treatment for Takayasu arteritis in patients experiencing steroid toxicity.
Takayasu arteritis (TA), also known as “pulseless disease,” is a chronic large vessel vasculitis of unknown etiology that predominantly involves the aorta and its major branches. TA occurs worldwide and can affect all ethnic groups; the disease is most common in Asians. In this case report, we present a case of 15-year-old female, with a history of autoimmune thyroiditis presented with transient ischemic attack, the absence of peripheral and feeble central pulses with bruits that could be heard along the carotid, renal, and abdominal arteries, and a difference of > 10 mmHg in systolic blood pressure between arms. She was diagnosed clinically with TA. Digital subtraction angiography revealed aortoarteritis with involvement of bilateral subclavian, left proximal common carotid artery, and abdominal aorta. The patient was started on high-dose corticosteroid and methotrexate but due to steroid toxicity shifted to injection tocilizumab. She is on treatment and asymptomatic.
No takes yet. Share an insight, caveat, or question.
Ansari et al. (2024) conducted a case report in Takayasu arteritis associated with autoimmune thyroiditis (n=1). Tocilizumab was evaluated on Symptom resolution. Treatment with tocilizumab successfully resolved symptoms in a 15-year-old female with Takayasu arteritis who developed steroid toxicity from initial therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: